Publications

Prof. Francis Chinegwundoh MBE > Publications

Professor Francis Chinegwundoh has authored and co-authored a wide range of peer-reviewed articles, abstracts, book chapters, and reports. His publications reflect major contributions to urological oncology, prostate cancer disparities, surgical practice, and public health.

2020–2025

  • Chinegwundoh FI, Smith S, Anie KA. Treatments for priapism in boys and men with sickle cell disease. Cochrane Database of Systematic Reviews 2020;4:CD004198. doi:10.1002/14651858.CD004198.pub4. https://pubmed.ncbi.nlm.nih.gov/15495085/
  • Bolodeoku J, Pinkney S, Chand V, Anyaeche C, Kim TK, Chinegwundoh F. Serum total testosterone measurement using i-CHROMA point-of-care method in healthy male volunteers. Research and Reviews Journal of Hospital and Clinical Pharmacy 2020;6(4):1-6.
  • Jonosky JB, De Villiers N, Wadee R, Chinegwundoh F, Adam A. Large bowel obstruction from advanced prostate cancer in a 41-year-old: role of genetic testing. South African Journal of Surgery 2020;58(3):163.
  • Chinegwundoh F. African Organisation for Research & Training in Cancer (AORTIC) at London Global Cancer Week, 15–20 November 2020. Journal of Global Medicine 2021;1(1). DOI:10.51496/jogm.v1.3. https://globalmedicine.co.uk/index.php/jogm/article/view/3
  • Chinegwundoh F. Time to talk about the risk of prostate cancer in Black men and what we can do about it. NHS Blog 2018 (accessed 18 April 2021). https://www.england.nhs.uk/blog/time-to-talk-about-the-prostate-cancer-risk-in-black-men-and-what-we-can-do-about-it/
  • Potter A, Chinegwundoh F, Vlaev I. Can targeting women with behavioural science ‘nudges’ help Black men find out more about their prostate cancer risk? Patient Education and Counselling 2021;104(10):2532-2535.
  • Grey A, Scott R, Chinegwundoh F, Ahmed H; The CADMUS Study Group. The CADMUS trial: comparing multiparametric ultrasound-targeted biopsies with multiparametric MRI in detecting clinically significant prostate cancer. Journal of Clinical Oncology 2021;39(15 Suppl):5008.
  • Stanway S, Chinegwundoh F, Cowan R. The UK’s contribution to cancer control in low- and middle-income countries. The Lancet Oncology 2021;22(9):e410-e418.
  • Chinegwundoh F. The relationship between Black men with prostate cancer and their healthcare providers. Nature Reviews Urology 2021. (abstract) https://www.nature.com/articles/s41585-021-00525-6
  • Martins T, Abel G, Ukoumunne OC, Price S, Lyratzopoulos G, Chinegwundoh F, Hamilton W. Ethnic inequalities in diagnostic interval of common cancers: a population-based UK cohort study. Cancers 2022;14(13):3085. (abstract) https://doi.org/10.3390/cancers14133085
  • Booth C, Chinegwundoh F, Allen S, Van Poppel H. Diagnosing prostate cancer at a curable stage requires PSA testing in asymptomatic patients. BMJ 2022;378:o1714. doi:10.1136/bmj.o1714.
  • Martins T, Abel G, Ukoumunne OC, Mounce L, Price S, Lyratzopoulos G, Chinegwundoh F, Hamilton W. Ethnic inequalities in routes to cancer diagnosis: a UK cohort study. British Journal of Cancer 2022;127(5):863-871.
  • Chinegwundoh F. Prostate cancer screening: better outcomes from early detection. BMJ 2023;382:p1842. (Letter).
  • Moore C, Chinegwundoh F, et al. Best current practice and research priorities in active surveillance for prostate cancer: report of a Movember International Consensus Meeting. European Urology Oncology 2023;6(2):160-182.
  • Bolodeoku J, Gbaa T, Anyaeche C, Bass M, Makanjuola J, Kim TK, Chinegwundoh F. Correlation and RAG analysis of Boditech i-CHROMA PSA point-of-care testing versus Roche PSA laboratory methods. Journal of Global Medicine 2023;2:113. (abstract) http://dx.doi.org/10.51496/jogm.v2.113
  • Oliver T, Nedjai B, Lane E, Chinegwundoh F, Cuzick J. Could immunotherapy help manage bacterial dysbiosis in prostate cancer? Cancer Research 2024;84(6 Suppl):6670. doi:10.1158/1538-7445.AM2024-6670.
  • Ladoukakis E, Oliver T, Wilks M, Lane E, Chinegwundoh F, Shaw G, Nedjai B. Anaerobe-related dysbiosis and prostate cancer development: a pilot study. Cancers 2025;17(70).(abstract) https://doi.org/10.3390/cancers17010070
  • Asante K, Chinegwundoh F, Hammonds R. Decolonisation of global health must include civil society. BMJ 2025;390:r1264. doi:10.1136/bmj.r1264.

2010–2019

  • Evans S, Metcalfe C, Patel B, Ibrahim F, Anson K, Chinegwundoh F, Corbishley C, Gillatt D, Kirby R, Muir G, Nargund V, Popert R, Wilson P, Persad R, Ben-Shlomo Y. Clinical presentation and initial management of Black and White men with prostate cancer in the UK: the PROCESS cohort study. British Journal of Cancer 2010;102(2):249-254. https://pubmed.ncbi.nlm.nih.gov/19935788/
  • Hameed A, Chinegwundoh F, Thwaini A. Prevention of catheter-related urinary tract infections. British Journal of Hospital Medicine 2010;71(3):148-152. https://pubmed.ncbi.nlm.nih.gov/20220720/
  • Kheirandish P, Chinegwundoh F, Kulkarni S. Treating stuttering priapism. BJU International 2011;108(7):1068-1072.
  • Kheirandish P, Chinegwundoh F. An unusual case of triorchidism. Journal of the Royal Society of Medicine Short Reports 2011;1(6):55.
  • Kheirandish P, Chinegwundoh F. Ethnic differences in prostate cancer. British Journal of Cancer 2011;105:481-485. http://www.nature.com/bjc/journal/v105/n4/full/bjc2011273a.html
  • Philippou P, Yap T, Chinegwundoh F. Third-generation salvage cryotherapy for radiorecurrent prostate cancer: a centre’s experience. Urologia Internationalis 2012. DOI:10.1159/000332220.
  • Akhter W, Khan F, Chinegwundoh F. Should every patient with haematospermia be investigated? A critical review. Central European Journal of Urology 2013;66(1):79-82.
  • Akhter W, Chinegwundoh F. Role of MRI in the diagnosis of prostate cancer: a proposal. Clinical and Experimental Medical Sciences 2013;1(3):111-116.
  • Akhter W, Benton S, Chinegwundoh F. PSA, free/total PSA ratio and P2PSA in monitoring pathological grades of prostate cancer on active surveillance. Journal of Endourology 2013;27(S1):P1-A470. DOI:10.1089/end.2013.2001.
  • Chinegwundoh F. The PSA controversy: is overtreatment a price worth paying for earlier diagnosis? (letter). British Journal of Family Medicine 2014;18 (July/August).
  • MacAttram M, Chinegwundoh F. Improving cancer screening access for London’s African-Caribbean communities with mental illness. Black Mental Health UK & Cancer Black Care, 2014. ISBN 9780992999506.
  • Jones A, Chinegwundoh F. Update on prostate cancer in Black men in the UK. ecancer 2014;8:455. DOI:10.3332/ecancer.2014.455.
  • Oliver T, Blackburn L, Chinegwundoh F. Vitamin D deficiency and anaerobes in prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 2015;24(10 Suppl):B89. DOI:10.1158/1538-7755.DISP14-B89.
  • Thakare N, Chinegwundoh F. Prostate cancer in the African-Caribbean community. Trends in Urology and Men’s Health 2015;6(4). DOI:10.1002/tre.472.
  • Tilki M, Thompson R, Robinson L, Bruce J, Chan E, Lewis O, Chinegwundoh F, Nelson H. The BME third sector: marginalised and exploited. Voluntary Sector Review 2015;6(1):93-101.
  • Ream E, Finnegan-John J, Allchorne P, Pedersen V, Trevatt P, Chinegwundoh F. Evaluation of a community-based outreach clinic for prostate cancer. European Journal of Cancer Nursing 2014;18. DOI:10.1016/S1462-3889(14)70037-7.
  • Thakare N, Njoku V, Turk S, Chinegwundoh F. Implementation of multidisciplinary team decisions in prostate cancer patients. Urology 2014;84(4 Suppl 1):MP-23.11.
  • Thakare N, Chinegwundoh F. Validation of PSA-age-volume (PSA-AV) formula for predicting prostate biopsy outcomes in a UK cohort. Urology 2014;84(4 Suppl 1).
  • Ahmed M, Thakare N, Chinegwundoh F. Outcomes for transperineal template-guided prostate biopsy. International Journal of Surgery 2015;23(Suppl):S15-S134.
  • Bolodeoku J, Bains S, Chand V, Bacon R, Chinegwundoh F. Evaluation of point-of-care i-CHROMA PSA testing in community screening. Journal of Near-Patient Testing & Technology 2017;16(2):93-96.
  • Er V, Lane JA, Martin R, Persad R, Chinegwundoh F, Njoku V, Sutton E. Barriers and facilitators to healthy lifestyles among African-Caribbean prostate cancer survivors: a qualitative study. BMJ Open 2017;7(10):e017217.
  • Oliver T, Prasher S, Chinegwundoh F, Wilks M. Identification of low oxygen-tolerating bacteria in prostate secretions: aetiological and therapeutic relevance. The Lancet 2017;390:S71.
  • Bamidele O, McGarvey H, Lagan B, Ali N, Chinegwundoh F. Life after prostate cancer: experiences of Black African and Caribbean men – a systematic review. European Journal of Cancer Care 2017.
  • Chinegwundoh F, Smith S, Anie K. Treatments for priapism in boys and men with sickle cell disease. Cochrane Database of Systematic Reviews 2017;CD004198.
  • Chinegwundoh F. Urine sample collection: issues and a solution. Trends in Urology & Men’s Health 2018;9(1):Jan/Feb.
  • Andrews C, Fortier B, Chinegwundoh F, et al. Development and implementation of a Pan-African cancer research network (CaPTC). Journal of Global Oncology 2018. DOI:10.1200/JGO.18.00062.
  • Mohammed F, Odedina F, Ibrahim S, Chinegwundoh F, Okpala I. Cortisol, annexin V, PD-L1 and DARC proteins in aggressive prostate cancer phenotypes in Black men: CaPTC cohort study. Cancer Research 2018;78(13):2638. DOI:10.1158/1538-7445.AM2018-2638.
  • Mohammed F, Odedina F, Chinegwundoh F, Okpala I. Cortisol and health-related quality of life as prognostic indicators for prostate cancer risk in West African men. Cancer Health Disparities 2019.
  • Bamidele O, McGarvey H, Chinegwundoh F, McCaughan E. “Man in the driving seat”: psychosocial experiences of Black African and Caribbean men with prostate cancer. Psycho-Oncology 2019.
  • Bamidele O, McGarvey H, Chinegwundoh F, McCaughan E. “Hard to reach, but not out of reach”: barriers to recruiting Black African and Caribbean men with prostate cancer. European Journal of Cancer Care 2018.
  • Beltran L, Leach E, de Fonseka S, Bolodeoku J, Chinegwundoh F. Evaluation of i-CHROMA point-of-care PSA testing. Biomedical Journal of Scientific & Technical Research 2018;9(4).
  • Bolodeoku J, Coker O, Bains S, Anyaeche C, Kim K, Chinegwundoh F. Performance of point-of-care i-CHROMA PSA testing in UK NEQAS and RIQAS. Current Trends in Medical Diagnostic Methods 2018;CTMDM-104. DOI:10.29011/CTMDM-104.100004.
  • Chinegwundoh F, Perera R. Evaluating psychological support services for men with prostate cancer and their families in England. BJU International 2019. DOI:10.1111/bju.14959.
  • Chowdhury TA, Khan H, Druce MR, Drake WM, Rajakariar R, Thuraisingham R, Dobbie H, Parvanta L, Chinegwundoh F, Almushatat A, Warrens A, Alstead EM. Flipped learning in medical education. Future Healthcare Journal 2019;6(3):192-195. DOI:10.7861/fhj.2018-0017.
  • Oliver T, Wilson P, Ansell W, Philp T, Chinegwundoh F, Shamash J, Shaw G, Ahmad A. Intermittent anti-androgen vs. pituitary blockade in prostate cancer: a prospective audit. Urologia Internationalis 2018;100(2):172-180. DOI:10.1159/000485255.
  • Chinegwundoh F, Bamigboye E. Whiplash bladder: a novel phenomenon (case series). Case Studies in Surgery 2019;5(2):20. DOI:10.5430/css.v5n2p20.
  • Odedina FT, Ragin CC, Martin DN, Moser RP, Oliver JS, McDonald AC, Rice EL, Nguyen J, Chinegwundoh F, et al. Standardised global behavioural and epidemiological measures for prostate cancer in Black men. Company of Scientists 2019.
  • Fatiregun OA, Chinegwundoh F, Odedina F. Quality of evidence on prostate cancer in Nigeria. Cancer Health 2019.
  • Oliver T, Bhudia R, Chinegwundoh F, Wilks M. Anaerobes in prostate cancer: new approaches to treatment. Journal of Clinical Oncology 2020;38(15 Suppl):e13606 (abstract).
  • Collaborative Group. CRC/BPG UK Familial Prostate Cancer Study Group (contributor).
  • Chinegwundoh F. Men’s health. In: Kumar & Clarke (eds). Textbook of Clinical Medicine, 10th edition. Elsevier, 2020.

2000–2009

  • Farrugia D, Ansell W, Singh M, Philp T, Chinegwundoh F, Oliver RTD. Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. BJU International 2000;85:1069-1073.
  • Feneley MR, Jan H, Granowski M, Mather SJ, Ellison D, Glass J, Coptcoat M, Kirby RS, Ogden C, Oliver RTD, Badenoch DF, Chinegwundoh FI, Nargund VH, Paris AMI, Britton KE. Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer. Prostate Cancer and Prostatic Diseases 2000;3(1):47-52.
  • Iles RS, Right M, Price K, Otite O, Chinegwundoh F, Persad R. Fetal antigen 2 (FA-2): a new serum marker for detection and monitoring of bone metastases. Prostate Cancer 2000;3(2):124 (poster abstract).
  • Oliver RTD, Farrugia D, Ansell W, Chinegwundoh F. Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients. Prostate Cancer and Prostatic Diseases 2000;3:1-4.
  • Chinegwundoh F. Prostate cancer: an update. Caribbean Health 2001;4(6):6-7.
  • Oliver RTD, Lane T, Wells P, Chinegwundoh F, Nargund V. Medical interventions relevant in prevention and management of early prostate cancer. In: Wallace, Oliver, Ash, Miles (eds). The Effective Management of Prostate Cancer. Aesculapius Medical Press, 2002. Chapter 8.
  • Enver MK, Chinegwundoh F, Hoh I. Aspirin and transurethral resection of the prostate. European Urology Supplements 2002;1:674 (abstract).
  • Chinegwundoh FI. Prostate cancer in ethnic minorities. Men’s Health Journal 2003;2(3):95-97.
  • Chinegwundoh FI, Enver MK, Lee A, Ben-Shlomo Y, Kapoor S, Pati J. Increased risk of prostate cancer in UK African-Caribbean immigrants. BJU International 2003;91(Suppl 2):79 (abstract).
  • Lane TM, Berney D, Chinegwundoh F, Hines J, Philp T, Corr J, Oliver T. CGH-based microarrays in analysis of prostate cancer progression. Journal of Urology 2003;169(4):58 (abstract).
  • Steggall M, Gann Y, Chinegwundoh F. Sexual dysfunction screening: the advantages of a culturally sensitive joint clinic. Sexual and Relationship Therapy 2004;19:179-189.
  • Lane TM, Ansell W, Farrugia D, Wilson P, Williams G, Chinegwundoh F, Philp T, Hines J, Oliver RT. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urologia Internationalis 2004;73:117-122. (abstract) https://pubmed.ncbi.nlm.nih.gov/15331894/
  • Chinegwundoh F, Anie KA. Treatments for priapism in boys and men with sickle cell disease. Cochrane Review. In: The Cochrane Library, Issue 4, 2004. John Wiley & Sons, Ltd. https://pubmed.ncbi.nlm.nih.gov/15495085/
  • Mohamed K Enver, Paul D Miller, Frank I Chinegwundoh. Upper tract surveillance in primary bladder cancer follow-up. BJU International 2004;94(6):790.
  • Nambirajan T, Sohaib SA, Muller-Pollard C, Reznek R, Chinegwundoh FI. Virtual cystoscopy from CT: a pilot study. BJU International 2004;94(6):828. https://pubmed.ncbi.nlm.nih.gov/15476517/
  • Chinegwundoh F, Lee A, Radhakrishnan S, Hines J, Hill J, Oliver RTD. Immediate versus deferred radiation for patients receiving intermittent hormone therapy for locally advanced prostate cancer. BJU International 2005;95(Suppl 5):124, pg 91.
  • Thwaini A, Shergill I, Radhakrishnan S, Chinegwundoh F, Thwaini H. Botox in urology. International Urogynecology Journal 2005;19:1-5. https://pubmed.ncbi.nlm.nih.gov/16328118/
  • Steggall M, Gann S, Chinegwundoh F. Erectile dysfunction management at an East London clinic. Journal of Diabetes Nursing October 2005.
  • Ghani K, Rockall A, Nargund V, Chinegwundoh F. Prostate biopsy: to stop anticoagulation or not? BJU International 2006;97:22-25.
  • Enver MK, Hoh I, Chinegwundoh F. Management of aspirin in TURP: UK practice. Annals of the Royal College of Surgeons of England 2006;88:280-283. https://pubmed.ncbi.nlm.nih.gov/16719999/
  • Reichle J, Turk S, Chinegwundoh F, Buchholz N. Prostate stents as ultima ratio in unfit patients. Indian Journal of Urology 2006;22:68-70.
  • Chinegwundoh F, Enver M, Lee A, Nargund V, Oliver T. Risk and presenting features of prostate cancer amongst African-Caribbean, South Asian and European men in North-East London. BJU International 2006;98:1216-1220. https://pubmed.ncbi.nlm.nih.gov/17125479/
  • Ghani K, Chinegwundoh F. Urological management of the patient with AIDS. BJU International 2006;98(3):689-690.
  • Chinegwundoh F. Management of male stress incontinence. Trends in Urology, Gynaecology & Sexual Health 2006;11(5):12-14.
  • Steggall M, Gann S, Chinegwundoh F. Erectile dysfunction and performance anxiety. Trends in Urology, Gynaecology & Sexual Health 2006;11(5):32-36.
  • Otite U, Baithun S, Chinegwundoh F, Nargund V, Iles R. Detection of hCG-β in prostate cancer patients is not clinically significant. Tumour Biology 2006;27:181-186. (abstract) https://pubmed.ncbi.nlm.nih.gov/16651852/
  • Thwaini A, Naase M, Chinegwundoh F, Ghali L, Shergill I, Iles R. Gonadotropins and prostate cancer revisited. Urologia Internationalis 2006;77:289-296. (abstract) https://pubmed.ncbi.nlm.nih.gov/17135776/
  • Steggall MJ, Butler J, Coals S, Chinegwundoh F. Heart disease and erectile dysfunction: management at a nurse-led clinic. British Journal of Cardiac Nursing 2006;1(12):596-601.
  • Radhakrishnan S, Lee A, Enver K, Thwaini A, Chinegwundoh F. Impact of race on biochemical control after radiotherapy for prostate cancer. Prostate Cancer and Prostatic Diseases 2006;9:467 (abstract).
  • Thwaini A, Ghali L, Baithun S, Chinegwundoh F, Ahmed R, Elterifi I, Morgan D, Iles R. HCG-β as prognostic marker in prostate cancer. Urology 2006;68(5A):97 (abstract).
  • Thwaini A, Naase M, Chinegwundoh F, Baithun S, Ahmed R, Morgan D, Iles R. Genetic variant of luteinizing hormone and prostate cancer prognosis. Urology 2006;68(5A):259 (abstract).
  • Radhakrishnan S, Lee A, Oliver T, Chinegwundoh F. An infectious cause for prostate cancer. BJU International 2007;99(2):239-240.
  • Ben-Shlomo Y, Evans S, Metcalfe C, Ibrahim F, Patel B, Gillatt D, Anson K, Corbishley C, Kirby R, Muir G, Chinegwundoh F, et al. Risk of prostate cancer amongst black men in the UK: the PROCESS study. European Urology Supplements 2007;6(2):176 (abstract 616).
  • Radhakrishnan S, Chinegwundoh F. Investigational therapies for prostate cancer. In: Nargund V, Raghavan D, Sandler H (eds). Urological Oncology. Springer, 2008. ISBN 9781846283871.
  • Metcalfe C, Patel B, Evans S, Ibrahim F, Anson K, Chinegwundoh F, et al. Risk of prostate cancer amongst South Asian men in southern England: the PROCESS study. BJU International 2008;102(10):1407-1412.
  • Metcalfe C, Evans S, Ibrahim F, Patel B, Anson K, Chinegwundoh F, et al. Pathways to diagnosis for black and white men with prostate cancer: the PROCESS study. British Journal of Cancer 2008;99(7):1040-1045.
  • Mohammed A, Chinegwundoh F. Prostatitis syndrome: an overview. Archivio Italiano di Urologia e Andrologia 2008;80(3):115-122.
  • Borchert D, Sheridan E, Papatsoris A, Zaman F, Barua J, Junaid I, Pati J, Buchholz N, Chinegwundoh F. The case for probiotics in urology. BJU International 2008;101(4):413-414.
  • Ben-Shlomo Y, Evans S, Ibrahim F, Patel B, Anson K, Chinegwundoh F, et al. The risk of prostate cancer amongst black men in the UK: the PROCESS cohort study. European Urology 2008;53(1):99-105.
  • Borchert D, Sheridan L, Papatsoris A, Faruquz Z, Barua JM, Junaid I, Pati J, Chinegwundoh F, Buchholz N. Prevention and treatment of urinary tract infection with probiotics: review and perspective. Indian Journal of Urology 2008;24(2):139-144.
  • Ghani K, Oliver RT, Chinegwundoh F. HIV-associated prostate cancer: clinicopathological findings. BJU International 2009;103:270-271 (letter).
  • Chinegwundoh F, Cave G. Vasectomy. In: Araya M, Shergill IS, Silhi N, Grange P, Bott S (eds). Essential Urology in General Practice. MA Healthcare, 2009. ISBN 9781856423724.
  • Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, Freedman ML, Rivers B, Green BL, Kumar N. Prostate cancer disparities in black men: comparative review. Infectious Agents and Cancer 2009;4(Suppl 1):S2.
  • Ben-Shlomo Y, Evans S, Patel B, Anson K, Muir G, Persad R, Metcalfe C, Chinegwundoh F; PROCESS Study Group. Differences in epidemiology and presentation of prostate cancer in Black and White men: lessons from the PROCESS study. BJU International 2009;103(6):723-724.
  • Mohammed A, Chinegwundoh F. Testicular varicocele: an overview. Urologia Internationalis 2009;82(4):373-379.

1990–1999

  • Rayter Z, Chinegwundoh F. An unusual case of omental hernia. Postgraduate Medical Journal 1990;66:682-683.
  • Chinegwundoh FI. The disappearing fax. British Journal of Hospital Medicine 1991;45:199.
  • Chinegwundoh FI, Gough AC, Kaisary AV, Smith DCA, Wolf RC, Spurr NK. Debrisoquine metaboliser status as a risk factor for bladder cancer (abstract). European Urology 1992:254.
  • Chinegwundoh FI, Gough AC, Kaisary AV, Smith DCA, Wolf RC, Spurr NK. Debrisoquine metaboliser status as a risk factor for bladder cancer. In: Giuliani L, Puppo P (eds). Urology. Monduzzi Editore, 1992:383-386.
  • Chinegwundoh FI. Genoa: BPH discussion, prostate screening and ileal segment bladders. Hospital Update 1993;19:14.
  • Chinegwundoh FI. Urology Update. Hospital Update 1993;19:614.
  • Chinegwundoh FI, Gough AC, Kaisary AV, Smith DCA, Wolf RC, Spurr NK. Metabolic oxidative status – a predictor of bladder cancer? Journal of Urology (abstracts) 1993;4:484A.
  • Farrar D, Chinegwundoh FI. Urinary tract infections. Surgery 1994;12(5):104-110.
  • Chinegwundoh FI, Ryan P, Luesley T, Chan S. Renal and diaphragmatic endometriosis de novo associated with hormone replacement therapy. Journal of Urology 1995;153:380-381.
  • Chinegwundoh FI, Kaisary AV. Smoking, bladder cancer and metabolic oxidation. Journal of Urology, Abstracts from the American Urological Association Meeting, May 1994.
  • Chinegwundoh FI. Update on Urology. Hospital Update 1994;20:423.
  • Chinegwundoh FI, Nayeem N. Experience of Burch colposuspension in a district general hospital. British Journal of Clinical Practice 1995;49:41-44.
  • Chinegwundoh FI. Recurrent testicular torsion. British Journal of Urology 1995;76:268.
  • Chinegwundoh FI, Kirkham JS. Two cases of volvulus of the stomach associated with colon in the chest. British Journal of Clinical Practice 1995;49:152-153.
  • Farrar D, Chinegwundoh FI. How should I deal with recurrent urinary tract infection in women? Medicine in Practice 1995;2:11.
  • Spurr N, Chinegwundoh FI, Gough A, Smith D. Polymorphisms in drug-metabolising enzymes as modifiers of cancer risk. Clinical Chemistry 1995;41:1864-1869.
  • Chinegwundoh FI. The post-traumatic painful testis. Journal of the Royal Society of Medicine 1996;72:291.
  • Chinegwundoh FI, French M, Warfield A. Metastatic ureteral tumour. Urologia Internationalis 1996;56:55-56.
  • Chinegwundoh FI, Kaisary AV. Smoking and polymorphism in bladder cancer. British Journal of Urology 1996;77:672-675.
  • Chinegwundoh FI. The early history of bladder cancer. American Urological Association Meeting Abstract Book, Florida, 1996.
  • Chinegwundoh FI. Genetic polymorphism and bladder cancer. European Urology Abstracts 1996;30(Suppl 2):286.
  • Chinegwundoh FI. Causes of readmission following prostatectomy. European Urology Abstracts 1996;30(Suppl 2):352.
  • Chinegwundoh FI. Glutathione S-transferases – responsible for chemoresistance? European Urology Abstracts 1996;30(Suppl 2):782.
  • Chinegwundoh FI. The early history of bladder cancer. European Urology Abstracts 1996;30(Suppl 2):1047.
  • Chinegwundoh FI, Khor T, Leedham P. Bladder metastasis from renal cell carcinoma. British Journal of Urology 1997;79(4):650-651.
  • Chinegwundoh FI. Surgical waiting lists (letter). BMJ December 1997.
  • Chinegwundoh FI. The early (surgical) history of bladder cancer. In: De Historia Urologiae Europaeae, vol. 4, 1997. Historical Committee of the European Association of Urology.
  • Chinegwundoh FI. Prostate cancer. CME Bulletin Geriatric Medicine 1998;1(3):75-77.
  • Chinegwundoh F, Oliver T, Farrugia D, Ansell W, Grant-Williams G. Intermittent hormone therapy in advanced prostate cancer. European Urology 1999;35(Suppl 2):196. Abstract 47.
  • Chinegwundoh F, Liyanage G, Oliver T. Screening African-Caribbean versus Caucasian prostate cancers for markers of enhanced malignancy. European Urology 1999;35(Suppl 2):196. Abstract 583.
  • Torabi-Pour N, Nouri AME, Chinegwundoh F, Oliver RTD. Standardisation and potential use of HPLC for detection of cellular placental alkaline phosphatase using tumour cell lines and bladder biopsies. Urologia Internationalis 1999;63:234-241.

Interested in collaborating or learning more about Professor Chinegwundoh’s published work? Contact Professor Chinegwundoh’s office to discuss research, speaking, or partnership opportunities.

UROLOGICAL
CANCER

Diagnosis and treatment for urological cancers and benign prostate conditions, including biopsy, surgical options, and targeted therapy.

BLADDER
& URETHRA

Minimally invasive procedures to enhance urinary flow, remove bladder stones, treat bladder conditions, and address urethral narrowing.

INCONTINENCE
& PELVIC FLOOR

Support for stress incontinence and overactive bladder using retraining, pelvic floor therapy, medication, and surgical interventions.

REPRODUCTION &
FERTILITY

Vasectomy, varicocele and hydrocele management, fertility investigations, and treatment for male reproductive and scrotal health concerns.